Health Canada's investment in new post-market drug surveillance network a "pittance"

Silversides, Ann
August 2008
CMAJ: Canadian Medical Association Journal;8/26/2008, Vol. 179 Issue 5, p412
Academic Journal
The article focuses on the $1 million investment by Health Canada in an independent research network that will study the safety and effects of prescription drugs taken by Canadians. In June 2008, the Parliament's Standing Committee on Health called on the government to form the network that would link researchers around the country to produce timely reports that track the effect of drug use in the "real world" and hence, help protect Canadians from the unexpected adverse impacts of prescription drugs.


Related Articles

  • Medicines information provided by pharmaceutical representatives: a comparative study in Australia and Malaysia. Othman, Noordin; Vitry, Agnes I.; Roughead, Elizabeth E.; Ismail, Shaiful B.; Omar, Khairani // BMC Public Health;2010, Vol. 10, p743 

    Background: Pharmaceutical representatives provide medicines information on their promoted products to doctors. However, studies have shown that the quality of this information is often low. No study has assessed the medicines information provided by pharmaceutical representatives to doctors in...

  • Fatal ARs reported with fentanyl patch.  // Reactions Weekly;7/12/2008, Issue 1210, p3 

    The article reports that Health Canada has received 105 reports of adverse reactions (ARs) with a fatal outcome suspected of being associated with use of fentanyl transdermal patches for the period January 1, 1992 to December 31, 2007. According to the report, the cause of death was unrelated to...

  • An Automated Standardized System for Managing Adverse Events in Clinical Research Networks. Richesson, Rachel L.; Malloy, Jamie F.; Paulus, Kathleen; Cuthbertson, David; Krischer, Jeffrey P. // Drug Safety;2008, Vol. 31 Issue 10, p807 

    Multi-site clinical protocols and clinical research networks require tools to manage and monitor adverse events (AEs). To be successful, these tools must be designed to comply with applicable regulatory requirements, reflect current data standards, international directives and advances in...

  • No agreement on serious drug interactions, study finds. Ukens, Carol // Drug Topics;7/12/2004, Vol. 148 Issue 13, p30 

    This article discusses the findings of a study in the U.S. concerning the alert system for drug-drug interactions (DDI) with greatest clinical importance. According to the study, there is very little agreement on which DDI pose the most risk for patients. The researchers noted that out of 406 of...

  • Cardiac safety of sunitinib questioned.  // Reactions Weekly;1/5/2008, Issue 1183, p1 

    This article reports on the suspicion by U.S.-based researchers that sunitinib may be associated with clinically relevant cardiotoxicity. The researchers are recommending that sunitinib recipients be closely monitored for hypertension and reduction of left ventricular ejection fraction. The...

  • Lopinavir/ritonavir.  // Reactions Weekly;6/19/2004, Issue 1006, p14 

    Discusses research on lopinavir/ritonavir-induced lithiasis in men and women aged 28-57. Reference to a study by A. Garrec and colleagues published in the March 2004 issue of "AIDS"; Diseases developed in the patients after starting treatment with lopinavir/ritonavir; Concomitant medication...

  • Health Canada advises against using Lanmei Keili Ji.  // Reactions Weekly;4/21/2007, Issue 1148, p2 

    The article reports on the warning issued by Health Canada against the use of Lanmei Keili Ji for the treatment of cold, cough and influenza. The drug, according to an alert from Hong Kong Department of Health, is found to be adulterated with gliclazide. The safety and effectiveness of...

  • Adequacy of Patient Information on Adverse Effects: An Assessment of Patient Information Leaflets in the UK. Carrigan, Neil; Raynor, D. K.; Knapp, Peter // Drug Safety;2008, Vol. 31 Issue 4, p305 

    Background: One of the most important categories of information that patients want to know about the drug they are taking is the likelihood or probability of adverse effects. All patients should receive such information in the patient information leaflet that is supplied with all drugs....

  • Building the process-drug--side effect network to discover the relationship between biological Processes and side effects. Sejoon Lee; Kwang H. Lee; Min Song; Doheon Lee // BMC Bioinformatics;2011 Supplement 2, Vol. 12 Issue Suppl 2, p1 

    Background: Side effects are unwanted responses to drug treatment and are important resources for human phenotype information. The recent development of a database on side effects, the side effect resource (SIDER), is a first step in documenting the relationship between drugs and their side...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics